Qual é o preço para Jupiter Neurosciences, Inc. (JUNS)

O preço para Jupiter Neurosciences, Inc. (JUNS) é $5.34

Qual é a capitalização de mercado para Jupiter Neurosciences, Inc. (JUNS)

A capitalização de mercado para Jupiter Neurosciences, Inc. (JUNS) é $2.59M

Histórico de Preços de Jupiter Neurosciences, Inc. (JUNS)

Jupiter Neurosciences, Inc. is a pharmaceutical company engaged in clinical-stage research and development. Its primary focus is on advancing a resveratrol-based platform product, with the main objective of addressing neuro-inflammation. The company's pipeline includes several drug candidates: JNS101 is undergoing Phase II trials for Friedreich's Ataxia, a rare neurological disorder that damages the nervous system and causes mobility issues. Also in Phase II, JNS102 is being developed for mucopolysaccharidosis Type I, JNS107 for MELAS Syndrome, and JNS108 for mild cognitive impairment and early Alzheimer's disease. Furthermore, the company is progressing JNS109 for amyotrophic lateral sclerosis, JNS110 for traumatic brain injury and concussion, and JNS120 as a treatment for COVID-19. Founded in 2016, the company, formerly known as Jupiter Orphan Therapeutics, Inc., adopted its current name in August 2021 and is headquartered in Jupiter, Florida.

Ano	Desempenho
2026 (TTM)	-20.40%
2025	-88.77%
2024	0.00%

Ano

Desempenho

2026 (TTM)

-20.40%

2025

-88.77%

2024

0.00%

Empresa	Preço da ação	Variação 1a%	País
Vertex Pharmaceuticals Incorporated VRTX.US	$505.24	28.63%	US
Argenx SE ARGX.US	$846.09	29.41%	NL
Lonza Group AG LONN.SW	$731.69	6.47%	CH
Samsung Biologics Co.,Ltd. 207940.KS	$1.07K	-6.40%	KR
UCB S.A. UCB.BR	$251.82	11.75%	BE

Empresa

Preço da ação

Variação 1a%

País